Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/5/2026 | $55.00 | Buy | Tigress Financial |
| 1/21/2026 | $50.00 → $55.00 | Buy | BTIG Research |
| 1/12/2026 | $48.00 | Buy | Citigroup |
| 1/12/2026 | $38.00 | Neutral | BNP Paribas Exane |
| 1/12/2026 | $50.00 | Overweight | Analyst |
| 1/12/2026 | $50.00 | Overweight | Piper Sandler |
| 1/12/2026 | $48.00 | Overweight | Morgan Stanley |
| 1/12/2026 | $47.00 | Outperform | RBC Capital Mkts |
3 - Medline Inc. (0002046386) (Issuer)
3 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
S-1 - Medline Inc. (0002046386) (Filer)
S-8 - Medline Inc. (0002046386) (Filer)
10-K - Medline Inc. (0002046386) (Filer)
Tigress Financial initiated coverage of Medline with a rating of Buy and set a new price target of $55.00
BTIG Research reiterated coverage of Medline with a rating of Buy and set a new price target of $55.00 from $50.00 previously
Citigroup initiated coverage of Medline with a rating of Buy and set a new price target of $48.00
NORTHFIELD, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (NASDAQ:MDLN) ("Medline") announced today that certain selling stockholders affiliated with Blackstone Inc., The Carlyle Group Inc., Hellman & Friedman LLC and a wholly owned subsidiary of the Abu Dhabi Investment Authority (the "Selling Stockholders") have commenced an underwritten public offering of 75,000,000 shares of Medline's Class A common stock pursuant to a registration statement filed with the Securities and Exchange Commission (the "SEC"). Additionally, the Selling Stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 11,250,000 shares of Medline's Class A common stock. Med
Delivered strong full year 2025 resultsCompleted Initial Public OfferingIntroduced full year 2026 guidanceFourth quarter net sales of $7.8 billion, an increase of 14.8%Fourth quarter net income of $180 million, a decrease of 37.7%Fourth quarter Adjusted EBITDA1 of $805 million, approximately flatFull year net sales of $28.4 billion, an increase of 11.5%Full year net income of $1.2 billion, a decrease of 3.6%Full year Adjusted EBITDA1 of $3.5 billion, an increase of 3.2% NORTHFIELD, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline" or the "Company") (NASDAQ:MDLN), the largest provider of medical-surgical ("med-surg") products and supply chain solutions serving all points of c
NORTHFIELD, Ill., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that Jim Boyle, Chief Executive Officer, and Mike Drazin, Chief Financial Officer, are scheduled to present at the Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL, on Wednesday, March 11, 2026, at 9:30am ET. A webcast of the presentation will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available on Medline's Investor Relations website for six months following the event. About MedlineMedline is the largest provider of medical-surgical products and supply chain solutions serving all poi
4 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
4 - Medline Inc. (0002046386) (Issuer)
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. ("Medline") (NASDAQ:MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results. Information about Medline's financial results, including a link to the live webcast, will be available on the Events page of Medline's Investor Relations website at ir.medline.com. A replay of the webcast will be available following the event through the same website. About MedlineMedli